William D. Tap, MD

Articles

Dr. Tap on Future Research Efforts in Sarcoma

November 4th 2020

William D. Tap, MD, discusses future research efforts in sarcoma.

Dr. Tap on the Importance of Community and Academic Collaboration in Sarcoma

October 30th 2020

William D. Tap, MD, discusses the importance of ​community and academic collaboration in sarcoma.

Dr. Tap on the Rise of Precision Medicine in Sarcoma

October 30th 2020

William D. Tap, MD, discusses the rise of precision medicine in sarcoma.

Dr. Tap on the Evolution of Precision Medicine in Soft Tissue Sarcomas

October 27th 2020

William D. Tap, MD, discusses the evolution of precision medicine in soft tissue sarcomas.

Dr. Tap on Olaratumab in Patients With Soft Tissue Sarcoma

March 18th 2016

William D. Tap, MD, chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the mechanism of action of olaratumumab as a treatment for patients with soft tissue sarcoma.

Novel Molecular Targets for Drug Development in Non-GIST Sarcomas

August 22nd 2015

The characterization of molecular abnormalities implicated in the tumorigenesis of sarcomas is being increasingly applied to the classification, prognostication and, in particular situations, management of these diseases.

Dr. Tap on Olaratumab/Doxorubicin Combination in Soft Tissue Sarcomas

June 5th 2015

William Tap, MD, Medical Oncologist, Chief, Sarcoma Medical Oncology Service Memorial Sloan Kettering Cancer Center discusses the benefits of a olaratumab and doxorubicin combination treatment for advanced soft tissue sarcomas.

Dr. Tap on Combined KIT and CTLA-4 Blockade in Patients with GIST

July 10th 2014

William D. Tap, MD, Chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the idea of using combined KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas.

x